CAM 20419

Metabolite Markers of Thiopurines Testing

Category:Laboratory   Last Reviewed:October 2020
Department(s):Medical Affairs   Next Review:October 2021
Original Date:December 2000    

The use of thiopurines, medications for treating inflammatory bowel disease and other conditions, is limited by a high rate of drug toxicity. Susceptibility to drug toxicity has been linked to the level of activity of the enzyme thiopurine methyltransferase (TPMT), which converts thiopurines into metabolites. This variation in TPMT activity has been related to 3 distinct TPMT mutations. Pharmacogenomic analysis of TPMT status is proposed to identify patients at risk of thiopurine drug toxicity and adjust medication doses accordingly. Measurement of metabolite markers has also been proposed.

For individuals who are treated with thiopurines who receive TPMT pharmacogenomics analysis or TPMT phenotype analysis, the evidence includes studies of diagnostic performance, systematic reviews, and randomized controlled trials (RCTs). Relevant outcomes are symptoms, morbid events, and change in disease status. A large number of studies have assessed the diagnostic performance of TMPT genotyping and phenotyping tests. A meta-analysis found a pooled sensitivity of about 80% and specificity near 100% for identifying patients with subnormal enzymatic activity. In addition, studies have found a greater likelihood of adverse drug reactions with low TPMT activity. One RCT reporting on health outcomes was identified; this trial did not find a significant difference in outcomes for patients managed with and without TPMT genotype testing; it may have been underpowered. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are treated with thiopurines who receive azathioprine and/or 6-mercaptoprine metabolites analysis, the evidence includes a systematic review as well as prospective and retrospective studies. Relevant outcomes are symptoms, morbid events, and change in disease status. There is insufficient evidence from prospective studies to determine whether metabolite markers will lead to improved outcomes (primarily improved disease control and/or less adverse drug effects). Findings of studies evaluating the association between metabolite markers and clinical remission are mixed, and no prospective comparative trials have compared health outcomes in patients managed with metabolite markers and with current approaches to care. The evidence is insufficient to determine the effects of the technology on health outcomes.

Thiopurines or purine analogues are immunomodulators. They include azathioprine (AZA; Imuran), mercaptopurine (6-MP; Purinethol), and thioguanine (6-TG; Tabloid). Thiopurines are used to treat malignancies, rheumatic diseases, dermatologic conditions, and irritable bowel disease (IBD), and are used in solid organ transplantation. They are considered an effective immunosuppressive treatment of IBD, particularly in patients with corticosteroid-resistant disease. However, use of thiopurines is limited by both its long onset of action (3-4 months) and drug toxicities, which include hepatotoxicity, bone marrow suppression, pancreatitis, and allergic reactions.

Thiopurines are converted to 6-MP in vivo, where it is subsequently metabolized to 2 active metabolites; either 6-thioguanine nucleotides (6-TGN) by the enzyme IMPDH, or to 6-methyl-mercaptopurine ribonucleotides (6-MMRP) by the enzyme thiopurine methyltransferase (TPMT). TPMT also converts 6-MP into an inactive metabolite, 6-methyl-mercaptopurine. 6-TGNs are considered cytotoxic and thus are associated with bone marrow suppression, while 6-MMRP is associated with hepatotoxicity. In population studies, the activity of the TPMT enzyme has been shown to be trimodal, with 90% of subjects having high activity, 10% intermediate activity, and 0.3% with low or no activity. In patients with intermediate-to-low activity, the metabolism of 6-MP is shunted toward the IMPDH pathway with greater accumulation of 6-TGN; these patients are considered at risk for myelotoxicity (i.e., bone marrow suppression).

This variation in TPMT activity has been related to 3 distinctTPMT mutations and has permitted the development of TPMT genotyping based on a polymerase chain reaction. For example, patients with high TPMT activity are found to have 2 normal (wild-type) alleles for TPMT; those with intermediate activity are heterozygous (i.e., have a mutation on 1 chromosome), while those with low TPMT activity are homozygous for TPMT mutations (i.e., a mutation is found on both chromosomes). Genetic analysis has been explored as a technique to identify patients at risk for myelotoxicity; those with intermediate TPMT activity may be initially treated with lower doses of thiopurines, while those with low TPMT activity may not be good candidates for thiopurine therapy.

TPMT activity can also be measured by phenotypic testing. Phenotypic testing determines the level of thiopurine nucleotides or TPMT activity in erythrocytes and can also be informative. Caution must be taken with phenotyping, because some coadministered drugs can influence measurement of TPMT activity in blood, and recent blood transfusions will misrepresent a patient’s actual TPMT activity.

Prospective TPMT genotyping or phenotyping may help identify patients at increased risk of developing severe, life-threatening myelotoxicity. 

Monitoring of thiopurine therapy has been based on clinical assessment of response in addition to monitoring blood cell counts, liver function, and pancreatic function tests. However, there has been interest in monitoring intracellular levels of thiopurine metabolites (i.e., 6-TGN, 6-MMRP) to predict response and complications, with the ultimate aim of tailoring drug therapy to each individual patient.

While genotyping and phenotyping of TPMT would only be performed once, metabolite markers might be tested multiple times during the course of the disease to aid in determining initial dose and to evaluate ongoing dosing.

Regulatory Status 
Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Several thiopurine genotype, phenotype, and metabolite tests are available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

Prometheus®, a commercial laboratory, offers thiopurine genotype, phenotype, and metabolite testing for those on thiopurine therapy. The tests are referred to as Prometheus® TPMT Genetics, Prometheus® TMPT enzyme, and Prometheus® thiopurine metabolites, respectively. Other laboratories that offer TPMT genotyping include Quest Diagnostics (TPMT Genotype), ARUP Laboratories (TPMT DNA), and Specialty Laboratories (TPMT GenoTypR™).   


  1. One-time phenotypic analysis of the enzyme TPMT is considered MEDICALLY NECESSARY in patients prior to initiating treatment with azathioprine (AZA), mercaptopurine (6-MP) or thioguanine (6-TG) OR in patients on thiopurine therapy with abnormal complete blood count (CBC) results that do not respond to dose reduction.
  2. One-time phenotypic analysis of the enzyme NUDT15 is considered MEDICALLY NECESSARY in patients prior to initiating treatment with azathioprine (AZA), mercaptopurine (6-MP) or thioguanine (6-TG) OR in patients on thiopurine therapy with abnormal complete blood count (CBC) results that do not respond to dose reduction.
  3. Monitoring of thiopurine metabolite levels in individuals with inflammatory bowel disease is considered MEDICALLY NECESSARY for the following indications:
    1. To measure blood levels in individuals suspected of having toxic responses to AZA and/or 6-MP (e.g., hepatotoxicity or myelotoxicity);
    2. To measure drug levels in individuals who have not responded to therapy (e.g., persistent fever, further weight loss, and bloody diarrhea).
  4. Monitoring of thiopurine metabolite levels in individuals with acute lymphoblastic leukemia is considered MEDICALLY NECESSARY in the following situations:
    1. For patients showing signs of a lack of myelosuppression while on therapy
    2. For patients with normal function for TPMT and NUDT15 who do not appear to tolerate thiopurines

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of a patient’s illness. 

  1. Phenotypic analysis of the enzyme TPMT  is considered NOT MEDICALLY NECESSARY in all other situations
  2. Phenotypic analysis of the enzyme NUDT15 is considered NOT MEDICALLY NECESSARY in all other situations.
  3. Analysis of the metabolite markers of azathioprine and 6-mercaptopurine, including 6-methyl-mercaptopurine ribonucleotides (6-MMRP) and 6-thioguanine nucleotides (6-TGN), is considered NOT MEDICALLY NECESSARY in all other situations.  

Policy Guidelines
TPMT testing cannot substitute for CBC monitoring in patients receiving thiopurines. Early drug discontinuation may be considered in patients with abnormal CBC results. Dosage reduction is recommended in patients with reduced TPMT activity. Alternate therapies may need to be considered for patients who have low or absent TPMT activity (homozygous for nonfunctional alleles). Accurate phenotyping results are not possible in patients who received recent blood transfusions. Genotyping and phenotyping of TPMT would only need to be performed once. 

There are no specific CPT codes for metabolite markers of AZA, 6-MP or thioguanine. 

Benefit Application
BlueCard®/National Account Issues
Genotypic, phenotypic and metabolite markers are specialized laboratory tests typically performed in reference laboratories. 

The thiopurine drugs 6-mercaptopurine (6-MP), azathioprine (AZA), and thioguanine remain a mainstay of immunomodulator therapy (Belmont, 2019; Tantisira, 2019). However, several metabolites of these drugs (particularly 6-thioguanine [6-TG] and 6-methylmercaptopurine [6-MMP]) have been associated with harmful side effects, such as lowered therapeutic efficacy, hepatotoxicity, bone marrow toxicity, and more. The management of these toxic metabolites is further complicated by the many polymorphisms (and therefore efficacy in metabolism) of the genes responsible for metabolizing these drugs. Due to these toxic side effects, there has been significant investigation on monitoring of these metabolites to identify the optimal dose of a thiopurine for an individual patient. This process is called therapeutic drug monitoring (TDM) (MacDermott, 2019).

Two enzymes are responsible for catalyzing these reactions: thiopurine methyltransferase (TPMT) and hypoxanthine phosphoribosyl transferase. TPMT enzyme activity is a major factor determining AZA and 6-MP metabolism, and therefore 6-TG and 6-MMP levels. The majority of the population has wild type TPMT and normal enzyme activity, while 11% are heterozygous and have corresponding low TPMT enzyme activity, and  0.3% (1 in 300) have negligible activity (Lennard, Gibson, Nicole, & Lilleyman, 1993; Lennard, Van Loon, & Weinshilboum, 1989). Intermediate and normal metabolizers can have up to a threefold difference in initial target doses of AZA and 6-MP to achieve therapeutic 6-TG concentrations (Gardiner, Gearry, Begg, Zhang, & Barclay, 2008). Measurement of TPMT enzyme activity before instituting AZA or 6-MP may help prevent toxicity by identifying individuals with low or absent TPMT enzyme activity as well as identify those with higher than average TPMT activity who may remain refractory to conventional dosages (MacDermott, 2019). Dosing strategies involving such testing may be cost-effective (Cuffari, Dassopoulos, Turnbough, Thompson, & Bayless, 2004; Dubinsky et al., 2005; Winter et al., 2004). However, prediction of toxicity is not consistently reliable, as other enzymes are also likely to play a role in determining toxicity, such as glutathione-S-transferase (Stocco et al., 2007), and drug interactions must be taken into account  (Dewit, Vanheuverzwyn, Desager, & Horsmans, 2002; Gilissen et al., 2005; Szumlanski & Weinshilboum, 1995). Thus, even though TPMT testing is recommended (Relling et al., 2019), a complete blood count (CBC), and also liver function tests, must still be obtained (Belmont, 2019; MacDermott, 2019).

Another enzyme that may contribute to thiopurine metabolism is nucleoside diphosphate-linked moiety X motif 15, NUDIX 15 (NUDT15). Variants in this enzyme’s genotype and subsequent phenotype may lead to drastically reduced tolerance of 6-MP (Tantisira, 2019). Moriyama et al. proposed that NUDT15 variants cause thiopurines’ mechanism of action to fail by preventing the thiopurine metabolites’ incorporation into DNA. This causes these metabolites to remain active and therefore toxic (Moriyama et al., 2016). The frequency of these NUDT15 variants varies across populations, with the “poor metabolizer” phenotype reaching as high as 1 in 50 in East Asian populations. Despite the data indicating NUDT15’s role in thiopurine toxicity, guidelines for its assessment have not reached a consensus, and expert opinions and practices are mixed (Tantisira, 2019).

Therapeutic drug monitoring (TDM) is the measurement of serum, plasma, or urinary concentrations of a given drug. This can be measured in a variety of ways, including high performance liquid chromatography (HPLC) or mass spectrometry approaches such as GC-MS (Eadie, 1998). TDM is proposed to allow a clinician to identify the “optimal” dose of a drug (such as a thiopurine) for a patient, thereby maximizing therapeutic efficacy and minimizing harmful side effects. Non-TDM approaches typically involve starting at low doses, then adjusting if the patient is tolerating the drug well or poorly, whereas TDM takes a more proactive approach in managing dose (MacDermott, 2019). Several studies have attempted to identify standardized ranges of “optimal” metabolite concentrations. For example, the optimal concentration of the 6-TGN metabolite was found to be between 230 and 400 picomoles per 8 x 108 erythrocytes by Dubinsky et al. In that same study, bone marrow toxicity was found to correlate with levels above 400 picomoles per 8 x 108 erythrocytes (Dubinsky et al., 2000). Although there are potential limitations to TDM for thiopurines (such as intra-individual variability, lack of correlation with toxicity for 6-MMP, and so on), TDM used in conjunction with TPMT and NUDT15 assessment may allow clinicians to increase the therapeutic efficacy of thiopurines (MacDermott, 2019; Tantisira, 2019).

Clinical Validity and Utility
Haines et al. performed a retrospective study of the utility of measuring thiopurine metabolites in “inadequately controlled” inflammatory bowel disease (IBD). 63 patients with IBD were included, and these patients were treated with AZA or 6-mercaptopurine. On weight-based criteria, 50% patients were underdosed. However, metabolite study suggested that “7 (11%) patients were noncompliant, 18 (29%) were being underdosed, 33 (52%) were refractory to treatment with either appropriate (41%) or elevated (11%) metabolite concentrations, and 6 (10%) had a raised 6-methyl mercaptopurine: 6-thioguanine nucleotide ratio consistent with aberrant thiopurine metabolism”. The clinical outcome of 87% of patients improved when the treatment was shifted to a metabolite-based algorithm, whereas 3 of 17 patients improved when the discordant action was taken. The authors concluded that “Thiopurine metabolite testing is a potentially powerful tool for optimizing thiopurine usage in IBD” (Haines et al., 2011).

Lee et al. evaluated 165 patients undergoing thiopurine treatment for Crohn’s Disease. Thiopurine metabolite levels were measured, and both TPMT and NUDT15 were genotyped. The authors found 95 patients responded to treatment whereas 45 did not. The median 6-TGN (the primary metabolite of 6-thioguanine) was significantly higher in responders than nonresponders. At a 6-TGN level of 230 pmol/8 x 108 blood cells, the odds ratio was 4.63 for responders to nonresponders. NUDT15 variants were also found to be associated with “severe, early, leukopenia” with an average reduction of 88.2% from baseline white blood cell count at 4 weeks. The authors concluded that their findings “support the role of therapeutic drug monitoring in thiopurine maintenance treatment to optimize thiopurine therapy, especially, for non-responding CD patients” (Lee et al., 2017).

Spencer et al. compared “standard” and “optimized” thiopurine dosing regimens in 216 pediatric IBD patients. The “optimal” level was decided at “6-TGN >235 pmol/8 × 108 RBC”, and the metabolite levels were correlated between the primary outcome of “steroid-free clinical remission (SFR)”. Both groups were found to have similar initial and 6-month metabolite levels. SFR was achieved in 74% of the 180 patients on thiopurines at 6 months. The authors concluded that “steroid-free clinical remission and 6-TGN levels at 6 months were no different between a standardized, fixed dosing strategy and a metabolite-driven, optimized dosing strategy” (Spencer, Norris, Williams, & Dubinsky, 2019).

Meijer et al. evaluated the effects of thiopurine metabolites on clinical signs and if patient characteristics affected metabolite generation. 940 “laboratory findings” from 424 patients were examined. 6-TGN (a metabolite of azathioprine [AZA] and mercaptopurine) was found to negatively correlate with RBC count, WBC count, and neutrophil count. However, in patients using 6-thioguanine, those 6-TGN concentrations correlated positively with WBC count. An inverse correlation was observed between age and 6-TGN concentrations in AZA or 6-thioguanine patients, as well as between body mass index and 6-TGN in AZA or mercaptopurine patients. The authors concluded that “thiopurine derivative therapy influenced bone marrow production and the size of red blood cells. Age and body mass index were important pharmacokinetic factors in the generation of 6-TGN” (Meijer et al., 2017).

Estevinho et al. performed a meta-analysis to “assess the clinical value of 6-thioguanine nucleotide thresholds; and ii] to compare mean 6-thioguanine nucleotide concentrations between patients in clinical remission vs. those with active disease.” A total of 22 records were used in cut-off comparisons and 12 were used in the 6-thioguanine nucleotide mean differences analysis. The authors calculated the global odds ratio for remission in patients with 6-thioguanine nucleotides above predefined thresholds to be 3.95. The authors also found an odds ratio for remission of 2.25 for the 235 pmol/8 x 108 RBC threshold, and an odds ratio of 4.71 for the 250 pmol /8 x 108 RBC threshold. Finally, the authors found a “pooled difference” of 63.37 pmol/8 x 108 RBC between patients in clinical remission and those not in remission. Overall, the authors concluded that the study reinforced the link between and 6-thioguanine nucleotide levels and clinical remission in inflammatory bowel diseases (Estevinho et al., 2017).

Toksvang et al. performed a meta-analysis focusing on “incidence of hepatotoxicity in patients [with childhood acute lymphoblastic leukaemia, ALL or inflammatory bowel disease, IBD] treated with 6TG [6-thioguanine]”. 42 reports were included, further broken down into “four randomised controlled trials (RCTs) including 3,993 patients, 20 observational studies including 796 patients, and 18 case reports including 60 patients”. The authors measured hepatotoxicity by “sinusoidal obstruction syndrome”, which occurred in 9-25% of ALL patients in two of the four RCTs at a dosage of 40–60 mg/m2/day. The authors also noted that at a dosage of 23 mg/m2/day, nodular regenerative hyperplasia (NRH) occurred in 14% of IBD patients. At a dosage of 12 mg/m2/day, NRH occurred in 6% of IBD patients, which was noted to be similar to background incidence. The authors therefore concluded that doses at or under 12 mg/m2/day can “probably be considered safe” (Toksvang et al., 2019).

Zhu et al. evaluated the “predictive sensitivity based on 6TGN [6-thioguanine nucleotide] by subgrouping patients according to their NUDT15 R139C genotypes”. The authors included 411 patients with Crohn’s Disease. Two subgroups of NUDT15 genotypes were created, “CC” (n = 342) and “CT” (n = 65), with the final four patients harboring a TT genotype. Thiopurine-induced leukopenia (TIL) was the primary clinical endpoint measured. The authors found that of the 342 patients with a CC genotype, only 35 developed TIL (10.2%), but of the 65 CT patients, 33 developed TIL (50.2%). All four of the TT patients developed TIL. The authors also found that in both CC and CT genotypes, the median 6TGH level was higher in patients with TIL than patients without TIL (for CC, 474.8 pmol/8 × 108 RBC vs 306.0 pmol/8 × 108 RBC, for CT 291.7 / 8 × 108 RBC vs 217.6/8 × 108 RBC). From this data, the authors calculated the “cut-off” (a threshold to identify an optimal amount of cases) of the CT genotype to be 319.2 pmol/8 × 108 RBC and the cut-off for CC to be 411.5 pmol/8 × 108 RBC). Overall, the authors concluded that “The predictive sensitivity of TIL based on 6TGN is dramatically increased after subgrouping according to NUDT15 R139C genotypes. Applying 6TGN cut-off levels to adjust thiopurine therapies based on NUDT15 is strongly recommended” (Zhu et al., 2019).

National Comprehensive Cancer Network (NCCN, 2019, 2020)
In version 2 of the 2020 guidelines for Pediatric Acute Lymphoblastic Leukemia, the NCCN recommends that “for patients homozygous for normal function TPMT and NUDT15, who do not appear to tolerate thiopurines, consider measuring erythrocyte thiopurine metabolites. Genetic testing may fail to identify rare or previously undiscovered no function alleles”. The NCCN also writes that “genetic testing for no function alleles of TPMT and NUDT15 should be considered prior to the initiation of thiopurine therapy” (NCCN, 2019).

In version 1 of the 2020 guidelines for Acute Lymphoblastic Leukemia, the NCCN notes that “quantification of 6-MP metabolites can be very useful in determining whether lack of myelosuppression is due to non-compliance or hypermetabolism” (NCCN, 2020).

Toronto Ulcerative Colitis Consensus Group/American College of Gastroenterology (ACG) (Bressler et al., 2015)
Bressler et al. (2015) published clinical practice guidelines for the medical management of non-hospitalized ulcerative colitis on behalf of the Toronto Ulcerative Colitis Consensus Group, which reaffirmed recommendations from the American College of Gastroenterology, Practice Parameters Committee (Kornbluth & Sachar, 2010) for thiopurine therapy (Bressler et al., 2015). The authors stated that “…a TPMT assay is necessary before initiation of treatment to identify patients at risk for severe dose-dependent myelosuppression…therefore, thiopurine metabolite levels may be helpful to guide therapy. Note that TPMT testing does not replace the need for mandatory monitoring of complete blood cell count” (Bressler et al., 2015).

American College of Gastroenterology (ACG) (Lichtenstein et al., 2018; Rubin, Ananthakrishnan, Siegel, Sauer, & Long, 2019)
The ACG published a guideline for the “Management of Crohn's Disease in Adults”. Their relevant recommendations include:

“Thiopurine methyltransferase (TPMT) testing should be considered before initial use of azathioprine or 6-mercaptopurine to treat patients with Crohn's disease (strong recommendation, low level of evidence)” (Lichtenstein et al., 2018).

The ACG also published a guideline for ulcerative colitis (UC) in adults. Their relevant recommendations include:

“The patient with nonresponse or loss of response to therapy should be assessed with therapeutic drug monitoring to identify the reason for lack of response and whether to optimize the existing therapy or to select an alternate therapy.”

“There is insufficient evidence supporting a benefit for proactive therapeutic drug monitoring in all unselected patients with UC in remission” (Rubin et al., 2019).

North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Committee (Benkov et al., 2013)
In 2013, the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Committee on Inflammatory Bowel Disease published consensus recommendations on the role of TPMT and thiopurine metabolite testing in pediatric IBD (Benkov et al., 2013) The recommendations included the following:  

  • “TPMT testing is recommended before initiation of TPs to identify individuals who are homozygote recessive or have extremely low TPMT activity, with the latter having more reliability than the former. (HIGH).”
  • “Individuals who are homozygous recessive or have extremely low TPMT activity should avoid use of TPs because of concerns for significant leukopenia. (HIGH)”
  • “TPMT testing does not predict all cases of leukopenia and has no value to predict hypersensitivity adverse effects such as pancreatitis. Any potential value to reduce the risk of malignancy has not been studied. All individuals on TPs should have routine monitoring with CBC and WBC count differential to evaluate for leukopenia regardless of TPMT testing results. (HIGH)”
  • “Metabolite testing can be used to determine adherence to TP therapy. (HIGH)”
  • “Metabolite testing can be used to guide dose increases or modifications in patients with active disease. Consideration would include either increasing the dose, changing therapy or for those with elevated transaminases or an elevated 6-MMP, using adjunctive allopurinol to help raise 6-TG metabolites and suppress formation of 6-MMP. (MODERATE)”
  • “Routine and repetitive metabolite testing has little or no role in patients who are doing well and taking an acceptable dose of a TP. (MODERATE)”

American Gastroenterological Association (AGA) (Joseph D. Feuerstein et al., 2020; J. D. Feuerstein, Nguyen, Kupfer, Falck-Ytter, & Singh, 2017)
In 2017, the AGA published guidelines (J. D. Feuerstein et al., 2017) on Therapeutic Drug Monitoring in Inflammatory Bowel Disease which recommend:  

  • “In adult patients treated with thiopurines with active IBD or adverse effects thought to be due to thiopurine toxicity, the AGA suggests reactive thiopurine metabolite monitoring to guide treatment changes.”
  • “In adult patients with quiescent IBD treated with thiopurines, the AGA suggests against routine thiopurine metabolite monitoring.” 

The AGA published an Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases in the same year. In it, they note that IBD patients treated with thiopurines may benefit from reactive TDM to guide treatment changes (Vande Casteele, Herfarth, Katz, Falck-Ytter, & Singh, 2017).

In the 2020 AGA guidelines for “Management of Moderate to Severe Ulcerative Colitis”, the AGA remarks that “therapeutic drug monitoring to guide the use of biologic therapy has been addressed in separate AGA guidelines”. The “separate AGA guidelines” refer to the 2017 edition above (Joseph D. Feuerstein et al., 2020).

Clinical Pharmacogenetics Implementation Consortium (CPIC, 2020; Relling et al., 2019)
In their guideline for “Thiopurine Dosing Based on TPMT and NUDT15 Genotypes”, CPIC notes that “mercaptopurine and azathioprine are generally used for nonmalignant immunologic disorders, mercaptopurine for lymphoid malignancies, and thioguanine for myeloid leukemias”. However, CPIC also writes that “variants in NUDT15 have been identified that strongly influence thiopurine tolerance in patients with acute lymphoblastic leukemia (ALL) and those with inflammatory bowel diseases” (Relling et al., 2019).

Although CPIC published an official guideline regarding TPMT and NUDT15 testing in 2019, an update was posted to their website in April 2020. That update is as follows: 

  • “For TPMT and NUDT15 indeterminate phenotypes, (i.e. combination of uncertain and/or unknown function alleles):
    • TPMT indeterminate: Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype.
    • NUDT15 indeterminate: If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity” (CPIC, 2020).

British Society of Gastroenterology (BSG) (Lamb et al., 2019)
The BSG published “consensus guidelines” on management of inflammatory bowel disease in adults. They recommend checking TPMT status in “all patients considered for thiopurine therapy”. They also recommend testing the NUDT15 genotype if “available”.

The BSG also writes that thiopurine metabolites should be checked if a patient experiences myelotoxicity as a side effect. Similarly, if a patient demonstrates “newly abnormal LFTs [liver function tests]”, thiopurine metabolites should be checked.

Overall, the BSG writes that thiopurine metabolites can be used to “optimize drug dosing” and “suggest that metabolite monitoring may be used for those with inadequate response to therapy or toxicity, but should not be a substitute for routine monitoring blood tests” (Lamb et al., 2019).

Canadian Association of Gastroenterology (Mack et al., 2019)
The Canadian Association of Gastroenterology published a guideline on “the Medical Management of Pediatric Luminal Crohn’s Disease”. The guidelines “suggested that testing for TPMT by genotype or enzymatic activity be done prior to initiating thiopurine therapy to guide dosing” (Mack et al., 2019).

National Institute for Health and Care Excellence (NICE, 2019)
NICE released guidelines on Crohn’s Disease in 2019. In it, they recommend to “Monitor the effects of azathioprine, mercaptopurine, and methotrexate as advised in the British national formulary (BNF) or British national formulary for children (BNFC)” (NICE, 2019).

European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition (Turner et al., 2018)
These joint guidelines note that “measuring…6-TG and 6-MMP levels after 2–3 months, may aid in optimizing thiopurine dosing”. Measuring thiopurine metabolites is recommended in the following scenarios:  

  • In patients with incomplete response on stable thiopurine dosage
  • In patients who present with leucopenia or elevated transaminases
  • When poor compliance is suspected (Turner et al., 2018).


  1. Belmont, H. M. (2019). Pharmacology and side effects of azathioprine when used in rheumatic diseases - UpToDate. In P. L. Romain (Ed.), UpToDate. Retrieved from
  2. Benkov, K., Lu, Y., Patel, A., Rahhal, R., Russell, G., & Teitelbaum, J. (2013). Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD. J Pediatr Gastroenterol Nutr, 56(3), 333-340. doi:10.1097/MPG.0b013e3182844705
  3. Bradford, K., & Shih, D. Q. (2011). Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol, 17(37), 4166-4173. doi:10.3748/wjg.v17.i37.4166
  4. Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., . . . Feagan, B. (2015). Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology, 148(5), 1035-1058.e1033. doi:10.1053/j.gastro.2015.03.001
  5. CPIC. (2020). CPIC® Guideline for Thiopurines and TPMT and NUDT15. Retrieved from
  6. Cuffari, C., Dassopoulos, T., Turnbough, L., Thompson, R. E., & Bayless, T. M. (2004). Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol, 2(5), 410-417. Retrieved from
  7. Dewit, O., Vanheuverzwyn, R., Desager, J. P., & Horsmans, Y. (2002). Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther, 16(1), 79-85. Retrieved from
  8. Dubinsky, M. C., Lamothe, S., Yang, H. Y., Targan, S. R., Sinnett, D., Theoret, Y., & Seidman, E. G. (2000). Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology, 118(4), 705-713. Retrieved from
  9. Dubinsky, M. C., Reyes, E., Ofman, J., Chiou, C. F., Wade, S., & Sandborn, W. J. (2005). A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol, 100(10), 2239-2247. doi:10.1111/j.1572-0241.2005.41900.x
  10. Eadie, M. J. (1998). Therapeutic drug monitoring--antiepileptic drugs. Br J Clin Pharmacol, 46(3), 185-193. doi:10.1046/j.1365-2125.1998.00769.x
  11. Estevinho, M. M., Afonso, J., Rosa, I., Lago, P., Trindade, E., Correia, L., . . . Magro, F. (2017). A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease. J Crohns Colitis, 11(11), 1381-1392. doi:10.1093/ecco-jcc/jjx089
  12. Feuerstein, J. D., Isaacs, K. L., Schneider, Y., Siddique, S. M., Falck-Ytter, Y., Singh, S., . . . Siddique, S. M. (2020). AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology, 158(5), 1450-1461. doi:10.1053/j.gastro.2020.01.006
  13. Feuerstein, J. D., Nguyen, G. C., Kupfer, S. S., Falck-Ytter, Y., & Singh, S. (2017). American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology, 153(3), 827-834. doi:10.1053/j.gastro.2017.07.032
  14. Gardiner, S. J., Gearry, R. B., Begg, E. J., Zhang, M., & Barclay, M. L. (2008). Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol, 6(6), 654-660; quiz 604. doi:10.1016/j.cgh.2008.02.032
  15. Gilissen, L. P., Bierau, J., Derijks, L. J., Bos, L. P., Hooymans, P. M., van Gennip, A., . . . Engels, L. G. (2005). The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther, 22(7), 605-611. doi:10.1111/j.1365-2036.2005.02630.x
  16. Haines, M. L., Ajlouni, Y., Irving, P. M., Sparrow, M. P., Rose, R., Gearry, R. B., & Gibson, P. R. (2011). Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis, 17(6), 1301-1307. doi:10.1002/ibd.21458
  17. Kornbluth, A., & Sachar, D. B. (2010). Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol, 105(3), 501-523; quiz 524. doi:10.1038/ajg.2009.727
  18. Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., . . . Hawthorne, A. B. (2019). British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 68(Suppl 3), s1-s106. doi:10.1136/gutjnl-2019-318484
  19. Lee, J. H., Kim, T. J., Kim, E. R., Hong, S. N., Chang, D. K., Choi, L. H., . . . Kim, Y. H. (2017). Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn's disease. PLoS One, 12(12), e0188925. doi:10.1371/journal.pone.0188925
  20. Lennard, L., Gibson, B. E., Nicole, T., & Lilleyman, J. S. (1993). Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child, 69(5), 577-579. Retrieved from
  21. Lennard, L., Van Loon, J. A., & Weinshilboum, R. M. (1989). Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther, 46(2), 149-154. Retrieved from
  22. Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018). ACG Clinical Guideline: Management of Crohn's Disease in Adults. Official journal of the American College of Gastroenterology | ACG, 113(4). Retrieved from
  23. MacDermott, R. (2019). 6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine - UpToDate. In K. Robson (Ed.), UpToDate. Retrieved from
  24. Mack, D. R., Benchimol, E. I., Critch, J., deBruyn, J., Tse, F., Moayyedi, P., . . . Griffiths, A. (2019). Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. J Can Assoc Gastroenterol, 2(3), e35-e63. doi:10.1093/jcag/gwz018
  25. Meijer, B., Wilhelm, A. J., Mulder, C. J. J., Bouma, G., van Bodegraven, A. A., & de Boer, N. K. H. (2017). Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study. Ther Drug Monit, 39(4), 399-405. doi:10.1097/ftd.0000000000000414
  26. Moriyama, T., Nishii, R., Perez-Andreu, V., Yang, W., Klussmann, F. A., Zhao, X., . . . Yang, J. J. (2016). NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet, 48(4), 367-373. doi:10.1038/ng.3508
  27. NCCN. (2019). Pediatric Acute Lymphoblastic Leukemia, Version 2. Retrieved from
  28. NCCN. (2020). Acute Lymphoblastic Leukemia. Retrieved from
  29. NICE. (2019). Crohn’s disease: management. Retrieved from
  30. Relling, M. V., Schwab, M., Whirl-Carrillo, M., Suarez-Kurtz, G., Pui, C. H., Stein, C. M., . . . Yang, J. J. (2019). Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther, 105(5), 1095-1105. doi:10.1002/cpt.1304
  31. Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019). ACG Clinical Guideline: Ulcerative Colitis in Adults. Official journal of the American College of Gastroenterology | ACG, 114(3). Retrieved from
  32. Spencer, E., Norris, E., Williams, C., & Dubinsky, M. C. (2019). The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD. Inflamm Bowel Dis, 25(1), 142-149. doi:10.1093/ibd/izy216
  33. Stocco, G., Martelossi, S., Barabino, A., Decorti, G., Bartoli, F., Montico, M., . . . Ventura, A. (2007). Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis, 13(1), 57-64. doi:10.1002/ibd.20004
  34. Szumlanski, C. L., & Weinshilboum, R. M. (1995). Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol, 39(4), 456-459. Retrieved from
  35. Tantisira, K., Weiss, Scott. (2019). Overview of pharmacogenomics. Retrieved from
  36. Toksvang, L. N., Schmidt, M. S., Arup, S., Larsen, R. H., Frandsen, T. L., Schmiegelow, K., & Rank, C. U. (2019). Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review. PLoS One, 14(5), e0212157. doi:10.1371/journal.pone.0212157
  37. Turner, D., Ruemmele, F. M., Orlanski-Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., . . . Russell, R. K. (2018). Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr, 67(2), 257-291. doi:10.1097/mpg.0000000000002035
  38. Vande Casteele, N., Herfarth, H., Katz, J., Falck-Ytter, Y., & Singh, S. (2017). American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology, 153(3), 835-857.e836. doi:10.1053/j.gastro.2017.07.031
  39. Winter, J., Walker, A., Shapiro, D., Gaffney, D., Spooner, R. J., & Mills, P. R. (2004). Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther, 20(6), 593-599. doi:10.1111/j.1365-2036.2004.02124.x
  40. Zhu, X., Chao, K., Li, M., Xie, W., Zheng, H., Zhang, J. X., . . . Wang, X. D. (2019). Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn's disease patients. World J Gastroenterol, 25(38), 5850-5861. doi:10.3748/wjg.v25.i38.5850

Coding Section

Code Number

Code Description


Quantitation of therapeutic drug, not elsewhere specified


Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.


Appendix Table 1. Categories of Genetic Testing Addressed in Policy No. 20419

Category Addressed
  Yes No

1. Testing of an affected individual’s germline to benefit the individual


1a. Diagnostic


1b. Prognostic


1c. Therapeutic


2. Testing cancer cells from an affected individual to benefit the individual


2a. Diagnostic


2b. Prognostic


2c. Therapeutic


3. Testing an asymptomatic individual to determine future risk of disease


4. Testing of an affected individual’s germline to benefit family members


5. Reproductive testing


5a. Carrier testing: preconception


5b. Carrier testing: prenatal


5c. In utero testing: aneuploidy


5d. In utero testing: mutations


5e. In utero testing: other


5f. Preimplantation testing with in vitro fertilization


This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies and accredited national guidelines.

"Current Procedural Terminology© American Medical Association.  All Rights Reserved" 

History From 2014 Forward     


Annual review, updating policy to include verbiage regarding NUDT15 testing. Also updating rationale, references and coding. 


Annual review, updating title, adding medical necessity statement: 3. Monitoring of thiopurine metabolite levels in individuals with acute lymphoblastic leukemia MEETS COVERAGE CRITERIA in the following situations: a. For patients showing signs of a lack of myelosuppression while on therapy, b. For patients with normal function for TPMT and NUDT15 who do not appear to tolerate thiopurines.


Updating with 2019 codes. 


Annual review, no change to policy intent. 


Updated formatting issues. 


Updating policy with 2018 coding. No other changes. 


Annual review, no change to policy intent. Updating background, description, regulatory status, rationale and references. 


Added HCPCS G0480 to coding section. No other changes made. 


Updated category to Laboratory. No other changes. 


Updated coding section 


Interim review, updating policy verbiage. No significant change to policy intent. 


Annual review, no change to policy intent. 


Annual review, no change to policy intent. Updated background, description, guidedlines, rationale and references. Added coding and appendix 1.


Updated rationale, references, description and background. Policy verbiage updated to include "Genotypic and/or phenotypic analysis of the enzyme TPMT is considered investigational in all other situations."


 Annual review. Added benefit application.  Updated rationale and references. No change to policy intent. 

Go Back